CTOs on the Move


 
Microbion is a clinical stage biopharmaceutical company. Microbion is developing MBN-101 as the first product in the bismuth-thiol class for the treatment of resistant and difficult to treat infections. MBN-101 has broad spectrum, anti-bacterial efficacy against a broad range of pathogens, including multiple priority pathogens or “superbugs”. In addition to anti-bacterial efficacy, MBN-101 also has highly advantageous and product-differentiating capability to prevent and eradicate microbial biofilms. The dual action from this first in class product provides a novel clinical approach to treating infections. Their effectiveness against MRSA, MDR TB, CRE, VRE, and other antibiotic resistant pathogens highlights their potential to ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Microbion raised $25M on 01/06/2017
Microbion raised $17.1M on 05/28/2020

Similar Companies

Advanced Cell Diagnostics

Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. Based in the heart of Silicon Valley, ACD was founded and managed by experienced entrepreneurs in the life science industry. ACD’s products and services are based on its proprietary RNAscope® Technology, the first multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity. In addition to its ongoing efforts to develop proprietary diagnostic tests for cancer management, ACD also establishes partnerships with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development. These internal and external efforts will continue to position ACD as a leader in molecular diagnostics and companion diagnostics. The company’s technology overcomes critical hurdles in the identification and validation of biomarkers for companion diagnostics. ACD’s RNAscope® platform provides a new way of localizing and measuring RNA in situ with exceptional levels of sensitivity, specificity, and the ability to multiplex. Turnaround time for a new assay is reduced to three weeks. These advantages make the technology a powerful tool to address the issue of patient and disease heterogeneity, thus shortening the path to personalized medicine.

Allena Pharmaceuticals

Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. Allena`s proprietary technological approach enables the design, formulation and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract. This approach utilizes the GI tract to degrade metabolites, such as oxalate and urate, reducing plasma and urine levels, and in turn, reducing their disease burden on the kidney over time.

Spine Team Texas

Spine Team Texas is a Southlake, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ynsect

Ÿnsect is the world leader in the production of protein and natural insect fertilizers. Founded in 2011 in Paris, France, by both scientists and environmental activists, Next40 and B Corp-certified, the company processes insects into high-end, high-value ingredients for pets, fish, plants and humans. From its purpose-built state-of-the-art farms, Ÿnsect offers a long-term, sustainable, organic solution to accelerate protein and plant consumption. Ÿnsect uses pioneering proprietary technology covered by 377 patents across 44 categories, to produce lesser and yellow mealworms in fully automated vertical farms. Ÿnsect runs three production sites, one in Dole, France (commissioned 2016), one in the Netherlands (2017), one in the USA (since 2022), and a third site, the world`s largest vertical farm, in Amiens in France, is currently under construction. The company, which employs 360+ people, has raised around $ 500 million from major global investment funds, banks and public bodies and exports its products around the world.

AES OPTICS

AES OPTICS is a Senatobia, MS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.